David Lebowitz

Stock Analyst at Citigroup

(3.96)
# 622
Out of 5,043 analysts
119
Total ratings
59.77%
Success rate
8.69%
Average return

Stocks Rated by David Lebowitz

Ionis Pharmaceuticals
Sep 3, 2025
Maintains: Buy
Price Target: $69$84
Current: $70.86
Upside: +18.54%
Cytokinetics
Sep 2, 2025
Maintains: Buy
Price Target: $77$84
Current: $57.83
Upside: +45.25%
Celldex Therapeutics
Aug 20, 2025
Maintains: Buy
Price Target: $56$48
Current: $26.72
Upside: +79.64%
Schrödinger
Aug 15, 2025
Downgrades: Neutral
Price Target: $35$20
Current: $22.52
Upside: -11.19%
Ascendis Pharma
Aug 8, 2025
Maintains: Buy
Price Target: $243$290
Current: $202.00
Upside: +43.56%
Incyte
Jul 30, 2025
Maintains: Buy
Price Target: $88$103
Current: $91.28
Upside: +12.84%
Viking Therapeutics
Jul 24, 2025
Maintains: Neutral
Price Target: $31$38
Current: $34.42
Upside: +10.40%
Cogent Biosciences
Jul 18, 2025
Maintains: Buy
Price Target: $15$22
Current: $15.13
Upside: +45.41%
BridgeBio Pharma
Jul 11, 2025
Maintains: Buy
Price Target: $58$67
Current: $54.26
Upside: +23.48%
Exelixis
May 15, 2025
Maintains: Buy
Price Target: $45$56
Current: $38.72
Upside: +44.63%
Maintains: Neutral
Price Target: $14$10
Current: $25.60
Upside: -60.94%
Maintains: Neutral
Price Target: $4$1.5
Current: $1.81
Upside: -17.13%
Maintains: Sell
Price Target: $32$45
Current: $66.40
Upside: -32.23%
Maintains: Buy
Price Target: $65$68
Current: $70.02
Upside: -2.88%
Initiates: Buy
Price Target: $382
Current: $421.50
Upside: -9.37%
Maintains: Neutral
Price Target: $103$96
Current: $54.48
Upside: +76.21%
Maintains: Equal-Weight
Price Target: $18$12
Current: $6.04
Upside: +98.68%
Maintains: Equal-Weight
Price Target: $170$164
Current: $463.43
Upside: -64.61%
Maintains: Overweight
Price Target: $36$39
Current: $20.11
Upside: +93.93%
Maintains: Equal-Weight
Price Target: $20$21
Current: $13.53
Upside: +55.21%
Maintains: Overweight
Price Target: $435$405
Current: $6.34
Upside: +6,288.01%
Maintains: Equal-Weight
Price Target: $13$14
Current: $1.66
Upside: +743.37%